Skip to content

Study · Randomized controlled trial · n = 18 · 2005

9 results

Pharmacokinetic profile of lanreotide Autogel in patients with acromegaly after four deep subcutaneous injections of 60, 90 or 120 mg every 28 days.

Bronstein M, Musolino N, Jallad R, Cendros JM, Ramis J, Obach R, Leselbaum A, Catus F

Clinical endocrinology1 Nov 2005Cited by 37 (Europe PMC)

PMID16268802 (opens in a new tab)DOI10.1111/j.1365-2265.2005.02372.x (opens in a new tab)PepBankPUB-16268802
Publisher pagePubMedAsk about this study
Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. 9 results from people.

  1. 01HumanRandomized controlled trialPharmacokinetics

    In acromegaly patients, single-dose lanreotide minimum concentrations showed statistically demonstrated dose proportionality.

    In plain wordsIn acromegaly patients, minimum lanreotide concentrations increased proportionally with dose after one administration.

    Peptide
    Lanreotide
    Outcome
    IncreaseSingle-dose minimum concentration proportionality
    Study

    n = 18

    Comparator
    other Lan-ATG dose groups (60, 90 or 120 mg)
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    60, 90 or 120 mg (single administration) · deep subcutaneousAs given in this study (human).

    Source sentences

    Summary
    After a single administration, dose proportionality for C(min,1), C(max) and AUC(tau) was demonstrated statistically.
    2 context sentences
    Summary · context
    A phase II, randomized, double-blind study, during which patients received 60, 90 or 120 mg Lan-ATG for four fixed administrations at 28-day intervals.
    Summary · context
    A total of 18 patients with acromegaly were recruited; six patients were randomized to each treatment.
  2. 02HumanRandomized controlled trialPharmacokinetics

    In acromegaly patients, single-dose lanreotide maximum concentrations showed statistically demonstrated dose proportionality.

    In plain wordsIn acromegaly patients, maximum lanreotide concentrations increased proportionally with dose after one administration.

    Peptide
    Lanreotide
    Outcome
    IncreaseSingle-dose maximum concentration proportionality
    Study

    n = 18

    Comparator
    other Lan-ATG dose groups (60, 90 or 120 mg)
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    60, 90 or 120 mg (single administration) · deep subcutaneousAs given in this study (human).

    Source sentences

    Summary
    After a single administration, dose proportionality for C(min,1), C(max) and AUC(tau) was demonstrated statistically.
    2 context sentences
    Summary · context
    A phase II, randomized, double-blind study, during which patients received 60, 90 or 120 mg Lan-ATG for four fixed administrations at 28-day intervals.
    Summary · context
    A total of 18 patients with acromegaly were recruited; six patients were randomized to each treatment.
  3. 03HumanRandomized controlled trialPharmacokinetics

    In acromegaly patients, single-dose lanreotide AUC showed statistically demonstrated dose proportionality.

    In plain wordsIn acromegaly patients, lanreotide exposure increased proportionally with dose after one administration.

    Peptide
    Lanreotide
    Outcome
    IncreaseSingle-dose exposure proportionality
    Study

    n = 18

    Comparator
    other Lan-ATG dose groups (60, 90 or 120 mg)
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    60, 90 or 120 mg (single administration) · deep subcutaneousAs given in this study (human).

    Source sentences

    Summary
    After a single administration, dose proportionality for C(min,1), C(max) and AUC(tau) was demonstrated statistically.
    2 context sentences
    Summary · context
    A phase II, randomized, double-blind study, during which patients received 60, 90 or 120 mg Lan-ATG for four fixed administrations at 28-day intervals.
    Summary · context
    A total of 18 patients with acromegaly were recruited; six patients were randomized to each treatment.
  4. 04HumanRandomized controlled trialPharmacokinetics

    In acromegaly patients, steady-state lanreotide minimum concentrations increased linearly with dose after repeated administrations.

    In plain wordsIn acromegaly patients, minimum lanreotide concentrations increased linearly with dose after repeated administrations.

    Peptide
    Lanreotide
    Outcome
    IncreaseSteady-state minimum concentration
    Study

    n = 18

    Comparator
    other Lan-ATG dose groups (60, 90 or 120 mg)
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    60, 90 or 120 mg every 28 days for four administrations · deep subcutaneousAs given in this study (human).

    Source sentences

    Summary
    After repeated administrations, Lan-ATG exhibited linear pharmacokinetics over the dose range and ss values of C(min), C(max) and AUC(tau) increased in a dose-dependent, linear manner.
    2 context sentences
    Summary · context
    A phase II, randomized, double-blind study, during which patients received 60, 90 or 120 mg Lan-ATG for four fixed administrations at 28-day intervals.
    Summary · context
    A total of 18 patients with acromegaly were recruited; six patients were randomized to each treatment.
  5. 05HumanRandomized controlled trialPharmacokinetics

    In acromegaly patients, steady-state lanreotide maximum concentrations increased linearly with dose after repeated administrations.

    In plain wordsIn acromegaly patients, maximum lanreotide concentrations increased linearly with dose after repeated administrations.

    Peptide
    Lanreotide
    Outcome
    IncreaseSteady-state maximum concentration
    Study

    n = 18

    Comparator
    other Lan-ATG dose groups (60, 90 or 120 mg)
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    60, 90 or 120 mg every 28 days for four administrations · deep subcutaneousAs given in this study (human).

    Source sentences

    Summary
    After repeated administrations, Lan-ATG exhibited linear pharmacokinetics over the dose range and ss values of C(min), C(max) and AUC(tau) increased in a dose-dependent, linear manner.
    2 context sentences
    Summary · context
    A phase II, randomized, double-blind study, during which patients received 60, 90 or 120 mg Lan-ATG for four fixed administrations at 28-day intervals.
    Summary · context
    A total of 18 patients with acromegaly were recruited; six patients were randomized to each treatment.
  6. 06HumanRandomized controlled trialPharmacokinetics

    In acromegaly patients, steady-state lanreotide AUC increased linearly with dose after repeated administrations.

    In plain wordsIn acromegaly patients, lanreotide exposure increased linearly with dose after repeated administrations.

    Peptide
    Lanreotide
    Outcome
    IncreaseSteady-state exposure
    Study

    n = 18

    Comparator
    other Lan-ATG dose groups (60, 90 or 120 mg)
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    60, 90 or 120 mg every 28 days for four administrations · deep subcutaneousAs given in this study (human).

    Source sentences

    Summary
    After repeated administrations, Lan-ATG exhibited linear pharmacokinetics over the dose range and ss values of C(min), C(max) and AUC(tau) increased in a dose-dependent, linear manner.
    2 context sentences
    Summary · context
    A phase II, randomized, double-blind study, during which patients received 60, 90 or 120 mg Lan-ATG for four fixed administrations at 28-day intervals.
    Summary · context
    A total of 18 patients with acromegaly were recruited; six patients were randomized to each treatment.
  7. 07HumanNon-randomized trialPharmacokinetics

    In acromegaly patients, mean steady-state maximum lanreotide concentrations were two- to fourfold greater than minimum concentrations.

    In plain wordsIn acromegaly patients, peak lanreotide concentrations were two- to fourfold greater than minimum concentrations at steady state.

    Peptide
    Lanreotide
    Outcome
    Not applicablePeak-to-trough concentration ratio
    Study

    n = 18

    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    60, 90 or 120 mg every 28 days for four administrations · deep subcutaneousAs given in this study (human).

    Measurements

    steady-state Cmax/Cmin ratio
    2 to 4 fold
    mean C(max,ss) versus C(min,ss)

    Source sentences

    Summary
    Mean C(max,ss) values were only two- to fourfold greater than C(min,ss) values, and there was good control over the entire release profile.
    2 context sentences
    Summary · context
    A phase II, randomized, double-blind study, during which patients received 60, 90 or 120 mg Lan-ATG for four fixed administrations at 28-day intervals.
    Summary · context
    A total of 18 patients with acromegaly were recruited; six patients were randomized to each treatment.
  8. 08HumanNon-randomized trialEfficacy outcome

    In acromegaly patients, serum GH and IGF-1 levels declined over the course of the study during lanreotide Autogel treatment.

    In plain wordsIn acromegaly patients, GH and IGF-1 levels declined over the study during lanreotide Autogel treatment.

    Peptide
    Lanreotide
    Outcome
    DecreaseSerum GH and IGF-1 levels
    Study

    n = 18

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    60, 90 or 120 mg every 28 days for four administrations · deep subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Serum levels of GH and IGF-1 declined over the course of the study
    2 context sentences
    Summary · context
    A phase II, randomized, double-blind study, during which patients received 60, 90 or 120 mg Lan-ATG for four fixed administrations at 28-day intervals.
    Summary · context
    A total of 18 patients with acromegaly were recruited; six patients were randomized to each treatment.
  9. 09HumanNon-randomized trialSafety outcome

    In acromegaly patients, lanreotide treatment was well tolerated.

    In plain wordsIn acromegaly patients, lanreotide treatment was well tolerated.

    Peptide
    Lanreotide
    Outcome
    Not applicableTolerability
    Study

    n = 18

    Outcome group
    Adverse events · Whole body
    Studied dose
    60, 90 or 120 mg every 28 days for four administrations · deep subcutaneousAs given in this study (human).

    Source sentences

    Summary
    The treatment was well tolerated.
    2 context sentences
    Summary · context
    A phase II, randomized, double-blind study, during which patients received 60, 90 or 120 mg Lan-ATG for four fixed administrations at 28-day intervals.
    Summary · context
    A total of 18 patients with acromegaly were recruited; six patients were randomized to each treatment.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.